. MSF Essential Drugs Guidelines دليل عملي موجه للأطباء والصيادلة والممرضين والمساعدين الطبيين
The aim of this report is to: (1) synthesize the findings from selected maternal and newborn related studies in Nepal conducted during 2011-2014, (2) identify areas of improvement in existing interventions, and (3) recommend possible strategies to fulfill such gaps.
Nigeria is committed to end preventable newborn deaths, making life-saving interventions available to all mothers and babies who need them.
This guide provides national stakeholders and advocates with information and guidance to update the national essential medicines list to include a new commodity, a new indication, or a new formulation based on the available evidence and based on country need and disease burden. While the actors, tim...eline, and process may vary from country to country, this guide presents the broad steps involved in revising an EML for any health commodity. Additional resources and a glossary are included to provide supplemental information and to clarify key terms.
more
This document is updated.
Please check the document:Priority medical devices list for the COVID-19 response and associated technical specifications
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv...e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
28 Jan. 2021. L’objet de ce document est de fournir des orientations provisoires sur la sécurité biologique en laboratoire applicable à l’analyse d’échantillons cliniques issus de patients.
Orientations provisoires, 28 janvier 2021
Dans cette version mise à jour des orientations sur la sécurité biologique en laboratoire en rapport avec le SARS-CoV-2, le virus responsable de la maladie à coronavirus 2019 (COVID-19), les points suivants ont été ajoutés : aspects de... sécurité biologique relatifs à la réalisation des tests diagnostiques rapides antigéniques, manipulation des nouveaux variants du SARS-CoV-2 au laboratoire, mise à jour de la décontamination des tests avant leur élimination, équipement de protection individuelle (EPI) pour le prélèvement d’échantillons et, même s’ils ne concernent pas directement la sécurité biologique, dangers chimiques et leur élimination en toute sécurité.
more
Introduction Pharmacovigilance (PV) systems to monitor drug and vaccine safety are often inadequate in sub-Saharan
Africa. In Malawi, a PV enhancement initiative was introduced to address major barriers to PV.
Objective The objective of this initiative was to improve reporting of adverse events (A...Es) by strengthening passive safety
surveillance via PV training and mentoring of local PV stakeholders and healthcare providers (HCPs) at their own healthcare
facilities (HCFs).
Methods An 18-month PV training and mentoring programme was implemented in collaboration with national stakeholders,
and in partnership with the Ministry of Health, GSK and PATH. Two-day training was provided to Expanded Programme on
Immunisation coordinators, identified as responsible for AE reporting, and four National Regulatory Authority representa-
tives. Abridged PV training and mentoring were provided regularly to HCPs. Support was given in upgrading the national
PV system. Key performance indicators included the number of AEs reported, transmission of AE forms, completeness of
reports, serious AEs reported and timeliness of recording into VigiFlow.
Results In 18 months, 443 HCPs at 61 HCFs were trained. The number of reported AEs increased from 22 (January 2000 to
October 2016) to 228 (November 2016 to May 2018), enabling Malawi to become a member of the World Health Organization
Programme for International Drug Monitoring. Most (98%) AE report forms contained mandatory information on reporter,
event, patient and product, but under 1% were transmitted to the national PV office within 48 h.
Conclusion Regular PV training and mentoring of HCPs were effective in enhancing passive safety surveillance in Malawi,
but the transmission of reports to the national PV centre requires further improvement.
more
Septième (7ème) édition de la liste nationale des médicaments essentiels, cinquiême (5ème) édition de la liste nationale des produits pharmaceutiques d'urgence, quatrième (4ème) édition de la liste nationale des réactifs essentiels pour l'analyses de biologie médicale.
La présente é...dition épouse les différents niveaux de laboratoires, aux produits d'urgence, aux médicaments vitaux pour la mère et l'enfant et aux dispositifs utilisés en Odontostomatologie.
more
Guide pratique d’utilisation à l'usage des médecins, pharmaciens, infirmiers et auxiliaires de santé.
Guía práctica de utilización destinado a médicos, farmacéuticos, enfermeros y auxiliares sanitario.
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv...e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
The Practical Approach to Emergencies in the Pregnant Mother, Newborn infant and Child. Provder Manual